Clinical Trials Browser

Phase 2/3 × NETWORK × Immunoglobulin G × Clear all

NCT02766335 2023-05-25

Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Phase 2/3 Completed

116 enrolled 23 charts

Recurrent Squamous Cell Lung Carcinoma